Evidence map›Paper›PMID 34787787›Full record

ArticleJournal of thrombosis and thrombolysis2022

Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients.

Caitlyn Whitaker, Amanda McKinney, Reagan Bollig, Nathan Hieb, R Frank Roberts, A Shaun Rowe

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Caitlyn WhitakerDepartment of Pharmacy, University of Tennessee Medical Center, Knoxville, TN, USA.
Amanda McKinneyDepartment of Pharmacy, University of Tennessee Medical Center, Knoxville, TN, USA.
Reagan BolligDepartment of Surgery, University of Tennessee Medical Center, Knoxville, TN, USA.
Nathan HiebDepartment of Surgery, University of Tennessee Medical Center, Knoxville, TN, USA.
R Frank RobertsDepartment of Surgery, University of Tennessee Medical Center, Knoxville, TN, USA.
A Shaun RoweDepartment of Pharmacy, University of Tennessee Medical Center, Knoxville, TN, USA. arowe@utmck.edu.
University of Tennessee at Knoxville · USUniversity of Tennessee Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Factor eight inhibitor bypassing activity (aPCC) is recommended as a non-specific reversal agent for direct oral anticoagulants (DOACs) according to the 2017 American College of Cardiology (ACC) guidelines for reversal of anticoagulation. Factor eight inhibitor bypassing activity carries a black box warning for thrombotic events such as stroke, pulmonary embolism, deep vein thrombosis, and myocardial infarction, particularly at high doses. This was a retrospective, single-center, cohort investigation that included patients who received a weight-based dose of aPCC for reversal of apixaban and rivaroxaban between January 1, 2015, and December 31, 2020. Patients were grouped by BMI as obese (BMI ≥ 30 kg/m

Indexed as

Myocardial InfarctionStrokeThrombosisAnticoagulantsBlood Coagulation FactorsFactor IXFactor VIIaFactor VIIIFactor Xa InhibitorsHemorrhageHumansIncidenceObesityPyrazolesPyridonesRetrospective StudiesAnticoagulantsapixabanBlood Coagulation FactorsFactor IXFactor VIIaFactor VIIIFactor Xa Inhibitorsprothrombin complex concentratesPyrazolesPyridonesRivaroxabanBlood coagulation factorsFactor Xa inhibitorsHemorrhageThromboembolism

Identifiers

PMID34787787
OpenAlexW3213051164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.